Now fully revised and in its fourth edition, the Oxford Handbook of Oncology has been the essential go-to guide for students and practitioners in oncology for over a decade. The scientific basis and diagnosis of cancers is covered, as well as drugs, biomarkers, and the presentation and psychosocial aspects of oncology. Concise, practical, and comprehensive, there is no better companion for both common conditions and challenging emergencies.
The field of oncology has surged forward since the last edition was published and the
Oxford Handbook of Oncology has been fully revised and updated to reflect these recent advances so you can be sure that the vital information you need is in your hands. This handbook incorporates changes such as the understanding of the science of cancer, novel therapies in breast, lung, renal, and melanoma, molecular sub-classification of common solid cancers, personalized therapy approaches, new agents in hard to treat cancers, the benefits of new technologies in radiotherapy, and the emerging data on the importance of the immune response.
Written by experts in the field to ensure that it is grounded in real life clinical practice, this handbook provides a concise guide to all aspects of oncology for all students, nurses, and junior faculty responsible for the care of cancer patients, while also providing further reading and highlighting areas of controversy for those who need a more detailed understanding.
Jim Cassidy, Global Head of Translational Medicine ( Oncology), Hoffmann La-Roche, USA, Donald Bissett, Consultant in Clinical Oncology, Aberdeen Royal Infirmary, Aberdeen, UK, Roy A. J. Spence OBE, Consultant Surgeon; Honorary Professor, Belfast Trust; Queen University, Belfast, University of Ulster, Northern Ireland, UK, Miranda Payne, Specialist Registrar in Medical Oncology, Oxford University Hospitals NHS Trust, UK, Gareth Morris-Stiff, Attending Surgeon; Associate Professor, Cleveland Clinic, Cleveland, Ohio; Lerner College of Medicine, Case Western Reserve University, USA
Jim Cassidy was previously Professor of Oncology at Aberdeen university (1994-2002), then CRUK Head of Oncology, Beatson Laboratories, Glasgow. He moved into pharma over 2 years ago to head early drug development.
Donald Bissett was schooled in Glasgow, and graduated from St Andrews University 1979 and University of Manchester 1982. Clinical experience in South Manchester Hospitals led to MRCP 1986, then commenced clinical oncology training in Nottingham and Glasgow, with FRCR 1989. Research Fellowship in the Department of Medical Oncology Beatson Institute, with MD and MSc in Clinical Pharmacology 1992. Senior lecturer in Clinical Oncology 1994, then Consultant in Clinical Oncology in Aberdeen 1995-2013 with particular interests in urological and thoracic malignancies.
